Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling

References

• Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition 2000; 28: 966–972
   PubMed Web of Science ®Google Scholar
• Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clinical Pharmacology and Therapy 1981; 30: 653–661
   PubMed Web of Science ®Google Scholar
• Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacology Bulletin 1998; 34: 211–219
   PubMedGoogle Scholar
• Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. British Journal of Clinical Pharmacology 1990b; 29: 557–563
   PubMed Web of Science ®Google Scholar
• Andersson T, Cederberg C, Regardh CG, Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology 1990a; 39: 195–197
   PubMed Web of Science ®Google Scholar
• Bachmann K. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. Journal of Applied Toxicology 1989; 9: 331–338
   PubMed Web of Science ®Google Scholar
• Bae HY, Choi DH, Choi JS. Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. Research Communications in Molecular Pathology and Pharmacology 2002; 111: 237–244
   PubMedGoogle Scholar
• Birkett DJ, Miners JO. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. British Journal of Clinical Pharmacology 1991; 31: 405–408
   PubMed Web of Science ®Google Scholar
• Bonate PL, Howard D. Critique of prospective allometric scaling: Does the emperor have clothes?. Journal of Clinical Pharmacology 2000; 40: 345–346
   PubMed Web of Science ®Google Scholar
• Bonati M, Latini R, Tognoni G, Young JF, Garattini S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metabolism Reviews 1984; 15: 1355–1383
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology 1982; 10: 201–227
   PubMedGoogle Scholar
• Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews 1984; 15: 1071–1121
   PubMed Web of Science ®Google Scholar
• Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clinical Pharmacology and Therapy 1998; 63: 529–539
   PubMed Web of Science ®Google Scholar
• Brynne N, Svanstrom C, Aberg-Wistedt A, Hallen B, Bertilsson L. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. British Journal of Clinical Pharmacology 1999; 48: 553–563
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Therapy and Drug Monitoring 2000; 22: 409–417
   PubMed Web of Science ®Google Scholar
• Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to human. Advances in Drug Research 1991; 20: 2–116
   Google Scholar
• Chiou WL, Robbie G, Chung SM, Wu TC, Ma C. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66. Pharmacology Research 1998; 15: 1474–1479
   PubMed Web of Science ®Google Scholar
• Delaporte E, Slaughter DE, Egan MA, Gatto GJ, Santos A, Shelley J, Price E, Howells L, Dean DC, Rodrigues AD. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. Journal of Biomolecular Screening 2001; 6: 225–231
   PubMed Web of Science ®Google Scholar
• Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clinical Pharmacology and Therapy 1995a; 57: 485–491
   PubMed Web of Science ®Google Scholar
• Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. British Journal of Clinical Pharmacology 1997; 44: 439–446
   PubMed Web of Science ®Google Scholar
• Friedman H, Redmond DE, Greenblatt DJ. Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. Psychopharmacology (Berlin) 1991; 104: 103–105
   Google Scholar
• Gascon AR, Calvo B, Hernandez RM, Dominguez-Gil A, Pedraz JL. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: Interspecies scaling in pharmacokinetic interactions. Pharmacology Research 1994; 11: 945–950
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemistry and Pharmacology 1994; 47: 1643–1653
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27–35
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clinical Pharmacology and Therapy 1988; 44: 326–334
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Alprazolam-ritonavir interaction: Implications for product labeling. Clinical Pharmacology and Therapy 2000a; 67: 335–341
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clinical Pharmacology and Therapy 1998a; 64: 237–247
   PubMed Web of Science ®Google Scholar
• Grevel J, Nuesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. European Journal of Clinical Pharmacology 1986; 31: 211–216
   PubMed Web of Science ®Google Scholar
• Ha HR, Chen J, Krahenbuhl S, Follath F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. European Journal of Clinical Pharmacology 1996; 49: 309–315
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology 2000; 49: 59–63
   PubMed Web of Science ®Google Scholar
• Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clinical Pharmacology and Therapy 1999; 66: 110–117
   PubMed Web of Science ®Google Scholar
• Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 1983; 16(Suppl. 1)43S–49S
   PubMed Web of Science ®Google Scholar
• Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, Sugiyama Y. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharmacology and Drug Disposition 2001; 22: 53–71
   PubMed Web of Science ®Google Scholar
• Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews 1997; 29: 891–922
   PubMed Web of Science ®Google Scholar
• Howgate EM, Rowland-Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006; 36: 473–497
   PubMed Web of Science ®Google Scholar
• Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology 2001; 51: 239–248
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesthesia and Analgesics 2002; 95: 667–673
   PubMed Web of Science ®Google Scholar
• Inoue SI, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 2006; 36: 499–513
   PubMed Web of Science ®Google Scholar
• Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemistry and Pharmacology 1998; 55: 1315–1325
   PubMed Web of Science ®Google Scholar
• Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics (in press) 2006
   PubMed Web of Science ®Google Scholar
• Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. Journal of Clinical Pharmacology 1998; 38: 14–21
   PubMed Web of Science ®Google Scholar
• Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition 1996; 24: 1081–1087
   PubMed Web of Science ®Google Scholar
• Keldenich J. Prediction of human clearance (CL) and volume of distribution (VD). Drug Discovery Today:. Technologies 2004; 1: 389–395
   Google Scholar
• Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101–109
   PubMedGoogle Scholar
• Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clinical Pharmacology and Therapy 1991; 50: 404–409
   PubMed Web of Science ®Google Scholar
• Klotz U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clinical Pharmacology and Therapy 1982; 32: 107–112
   PubMed Web of Science ®Google Scholar
• Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapy 1987; 241: 1112–1119
   PubMed Web of Science ®Google Scholar
• Kukanich B, Papich MG. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. Journal of Veterinary and Pharmacology Therapy 2004; 27: 337–341
   PubMed Web of Science ®Google Scholar
• Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics 1998; 353: 16–28
   PubMed Web of Science ®Google Scholar
• Lave T, Coassol P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro–in vivo correlations. Clinical Pharmacokinetics 1999; 36: 211–231
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. Journal of Pharmacology Science 1997; 86: 584–590
   PubMed Web of Science ®Google Scholar
• Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clinical Pharmacology and Therapy 2002; 72: 562–571
   PubMed Web of Science ®Google Scholar
• Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berlin) 1988; 96: 365–369
   Google Scholar
• Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metabolism and Disposition 1997; 25: 1379–1382
   PubMed Web of Science ®Google Scholar
• Liu XD, Chen J. Prediction of drug clearance in humans from laboratory animals based on body surface area. European Journal of Drug Metabolism Pharmacokinetics 2001; 26: 249–255
   PubMed Web of Science ®Google Scholar
• Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology and Therapy 2001; 69: 41–47
   PubMed Web of Science ®Google Scholar
• Mahmood I. Interspecies scaling: Predicting oral clearance in humans. American Journal of Therapy 2002a; 9: 35–42
   PubMedGoogle Scholar
• Mahmood I. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabolism Drug Interactions 2002b; 19: 49–64
   PubMedGoogle Scholar
• Mahmood I, Balian JD. Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species. Life Sciences 1996; 59: 579–585
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26: 887–895
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmacology Science 1996; 85: 411–414
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clinical Pharmacokinetics 1999; 36: 1–11
   PubMed Web of Science ®Google Scholar
• Mankowski DC, Lawton MP, Ekins S. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. Xenobiotica 2000; 30: 745–754
   PubMed Web of Science ®Google Scholar
• Mehl ML, Kyles AE, Craigmill AL, Epstein S, Gregory CR. Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. Journal of Veterinary and Pharmacology Therapy 2003; 26: 349–354
   PubMed Web of Science ®Google Scholar
• Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clinical Pharmacology and Therapy 2000; 68: 478–486
   PubMed Web of Science ®Google Scholar
• Miners JO, Wing LM, Lillywhite KJ, Smith KJ. Failure of ‘therapeutic’ doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. British Journal of Clinical Pharmacology 1984; 18: 853–860
   PubMed Web of Science ®Google Scholar
• Moghadamnia AA, Rostami-Hodjegan A, Abdul-Manap R, Wright CE, Morice AH, Tucker GT. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: Dextromethorphan vs. dextrorphan using quinidine inhibition. British Journal of Clinical Pharmacology 2003; 56: 57–67
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. British Journal of Clinical Pharmacology 2002a; 53: 3S–20S
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. British Journal of Clinical Pharmacology 2002b; 53: 21S–30S
   PubMed Web of Science ®Google Scholar
• Nagilla R, Frank KA, Jolivette LJ, Ward KW. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. Journal of Pharmacology Toxicology Methods 2006; 53: 106–116
   PubMedGoogle Scholar
• Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. Journal of Pharmacology Science 2004; 93: 2522–2534
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. Journal of Pharmacology Experimental Therapy 1997; 283: 46–58
   PubMed Web of Science ®Google Scholar
• Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro. British Journal of Anaesthesia 1999; 82: 900–903
   PubMed Web of Science ®Google Scholar
• Pahlman I, Kankaanranta S, Palmer L. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Arzneimittelforschung 2001; 51: 134–144
   PubMed Web of Science ®Google Scholar
• Palamanda J, Feng WW, Lin CC, Nomeir AA. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metabolism and Disposition 2000; 28: 38–43
   PubMed Web of Science ®Google Scholar
• Peart GF, Boutagy J, Shenfield GM. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. European Journal of Clinical Pharmacology 1987; 33: 397–402
   PubMed Web of Science ®Google Scholar
• Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, Pla-Delfina JM. Pharmacokinetics and bioavailability of diclofenac in the rat. Journal of Pharmacokinetics and Biopharmacology 1991; 19: 647–665
   PubMedGoogle Scholar
• Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF, Maurel P. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochemistry and Pharmacology 1996; 51: 591–598
   PubMed Web of Science ®Google Scholar
• Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metabolism and Disposition 1998; 26: 289–293
   PubMed Web of Science ®Google Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 2004; 34: 151–178
   PubMed Web of Science ®Google Scholar
• Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapy 1977; 200: 420–424
   PubMed Web of Science ®Google Scholar
• Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans — a study of single intravenous and oral doses. Therapy and Drug Monitoring 1990; 12: 163–172
   PubMed Web of Science ®Google Scholar
• Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I. Pharmacokinetics and metabolism of omeprazole in animals and man — an overview. Scandinavian Journal of Gastroenterology Suppl. 1985; 108: 79–94
   Google Scholar
• Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: A meta-analysis. British Journal of Clinical Pharmacology 2004; 57: 687
   Web of Science ®Google Scholar
• Sangalli L, Bortolotti A, Jiritano L, Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metabolism and Disposition 1988; 16: 749–753
   PubMed Web of Science ®Google Scholar
• Soto J, Alsar MJ. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. Journal of Clinical Pharmacology and Therapy 1997; 22: 191–195
   PubMed Web of Science ®Google Scholar
• Steffan J, Strehlau G, Maurer M, Rohlfs A. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. Journal of Veterinary and Pharmacology Therapy 2004; 27: 231–238
   PubMed Web of Science ®Google Scholar
• Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJ. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical Pharmacology and Therapy 2001; 69: 317–323
   PubMed Web of Science ®Google Scholar
• Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341–349
   PubMedGoogle Scholar
• Sun L, Lau CE. Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration–effect relations: Acute tolerance. European Journal of Pharmacology 2000; 398: 225–238
   PubMed Web of Science ®Google Scholar
• Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95–104
   PubMedGoogle Scholar
• Tallman MN, Ali SY, Smith PC. Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. Drug Metabolism and Disposition 2004; 32: 902–925
   PubMed Web of Science ®Google Scholar
• Tan KK, Trull AK, Shawket S. Co-administration of ciprofloxacin and cyclosporin: Lack of evidence for a pharmacokinetic interaction. British Journal of Clinical Pharmacology 1989; 28: 185–187
   PubMed Web of Science ®Google Scholar
• Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, Lin JH, Baillie TA. Interaction of diclofenac and quinidine in monkeys: Stimulation of diclofenac metabolism. Journal of Pharmacology and Experimental Therapy 1999; 291: 1068–1074
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 2005a; 33: 1297–1303
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 2005b; 33: 1294–1296
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 2005c; 33: 1288–1293
   PubMed Web of Science ®Google Scholar
• Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131–144
   PubMedGoogle Scholar
• Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapy 1996; 59: 491–502
   PubMed Web of Science ®Google Scholar
• Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clinical Pharmacokinetics 1997; 32: 31–36
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A. Red wine decreases cyclosporine bioavailability. Clinical Pharmacology and Therapy 2001; 70: 462–467
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacology and Pharmaceutics 1998; 50: 997–1004
   PubMed Web of Science ®Google Scholar
• Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clinical Pharmacology and Therapy 2000; 68: 82–91
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P-450 3A4: In vitro drug–drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition 2000; 28: 360–366
   PubMed Web of Science ®Google Scholar
• Wang Y, Roy A, Sun L, Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metabolism and Disposition 1999; 27: 855–859
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metabolism and Disposition 2000; 28: 392–397
   PubMed Web of Science ®Google Scholar
• Watanabe K, Matsuka N, Okazaki M, Hashimoto Y, Araki H, Gomita Y. The effect of immobilization stress on the pharmacokinetics of omeprazole in rats. Acta Medica Okayama 2002; 56: 19–23
   PubMed Web of Science ®Google Scholar
• Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S. The influence of rifampin treatment on caffeine clearance in healthy man. Journal of Hepatology 1995; 22: 78–81
   PubMed Web of Science ®Google Scholar
• Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology 2003; 56: 433–440
   PubMed Web of Science ®Google Scholar
• Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 1998; 135: 236–241
   PubMed Web of Science ®Google Scholar
• Yamao T, Nakagami H, Furuhama K, Onodera T, Kurosaki Y, Nakayama T, Kimura T. Pharmacokinetics of tolbutamide following intravenous and oral administrations in rats with obstructive jaundice. Biology and Pharmacology Bulletin 1994; 17: 691–695
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapy 1997; 283: 434–442
   PubMed Web of Science ®Google Scholar
• Yu A, Haining RL. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?. Drug Metabolism and Disposition 2001; 29: 1514–1520
   PubMed Web of Science ®Google Scholar
• Yu A, Dong H, Lang D, Haining RL. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metabolism and Disposition 2001; 29: 1362–1365
   PubMed Web of Science ®Google Scholar
• Zeng YL, Wang ZR, Lu ML. Pharmacokinetics of clozapine in rabbits. Yao Xue Xue Bao 1986; 21: 566–571
   PubMedGoogle Scholar
• Zuegge J, Schneider G, Coassolo P, Lave T. Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models. Clinical Pharmacokinetics 2001; 40: 553–563
   PubMed Web of Science ®Google Scholar
• Zysset T, Zeugin T, Kupfer A. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochemistry and Pharmacology 1988; 37: 3155–3160
   PubMed Web of Science ®Google Scholar